From the romantic florals of Peony to the versatile simplicity of Sir., these are the locally-grown swimwear brands you need to know. Vogue Australia may receive advertising or affiliate ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Novo and Lilly have both been on a manufacturing expansion tear in 2024, lining up multiple high-profile production projects around the world. To name just a few investments, Novo has blueprinted ...

Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation.

Join us as we take a look at some of the most glamorous celebrities in swimsuits over the winter break… JLo spent Christmas and New Year in Aspen, but that didn't stop her from slipping into a ...

In the time since, though, some analysts have said the reaction is overblown, particularly for weight-loss drugmakers like Wegovy, and Ozempic maker Novo Nordisk and Zepbound maker Eli Lilly.

Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...

Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

whose investigation into Cambridge Analytica earned her a nomination for the Pulitzer Prize in 2019. The journalist is also well known for her long-running legal row with Brexit campaigner Arron ...

Shelby Knowles / Bloomberg / Getty Images Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker ...